renal-cell-carcinoma

Documents about renal-cell-carcinoma

• A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab#868698ClinicalTrials.gov
• Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis#890523ClinicalTrials.gov
• The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy#892977ClinicalTrials.gov
• Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer#238105ClinicalTrials.gov
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies#913317ClinicalTrials.gov
• Comparative Analysis of Unsupervised and Supervised Autoencoders for Nuclei Classification in Clear Cell Renal Cell Carcinoma Images#821398arXiv (All)
• A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer#834037ClinicalTrials.gov
• A Study of HS-10516 in Patients With VHL Syndrome Associated Tumors#864120ClinicalTrials.gov
• A Study to Assess the Safety, Pharmacokinetics, and Efficacy of Intravenous (IV) ABBV-303, as Monotherapy and in Combination With IV Infused Budigalimab (ABBV-181), in Adults With Advanced Solid Tumors#826788ClinicalTrials.gov
• PARTIAL: study protocol for a clinical and cost-effectiveness of complex PARTIAL vs radical nephrectomy for clinically localised renal cell carcinoma randomised trial.#146108NCBI PubMed Central
• Near Infrared Technology and Laparoscopic Resection of Pancreatic Lesions: the COLPAN Project#861920ClinicalTrials.gov
• Complementary Roles of Radiomics and Foundation Representations in Renal Cell Carcinoma Classification: A Comparative Study of 2D and 3D CT Encodings#1043144arXiv CS
• A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers#803305ClinicalTrials.gov
• Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies#885479ClinicalTrials.gov
• Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function#863662ClinicalTrials.gov
• A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies#830569ClinicalTrials.gov
• Vorolanib in the Second-line Treatment of Patients With Unresectable or Metastatic Renal Cell Carcinoma#143539ClinicalTrials.gov
• Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation#417388bioRxiv / medRxiv
• A Study to Evaluate Efficacy and Safety of Lenvatinib Combined With Tislelizumab in Patients With FHRCC#917857ClinicalTrials.gov
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC#894734ClinicalTrials.gov
• Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy#253368Dipòsit Digital de la Universitat de Barcelona
• Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial#891536ClinicalTrials.gov
• Tigit And Gdf-15 As Biomarkers And Targets In Renal Cell Carcinoma Resistant To Immune Checkpoint Inhibitors#260915EliScholar
• Effect of Urinary Total Arsenic Level and Estimated Glomerular Filtration Rate on the Risk of Renal Cell Carcinoma in a Low Arsenic Exposure Area#384149CiNii
• The effect of immune checkpoint inhibitor combination therapies in metastatic renal cell carcinoma patients with and without previous cytoreductive nephrectomy: A systematic review and meta-analysis#388095HAL (France)
• Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery#902703ClinicalTrials.gov
• A Comparative Study Between AirSeal, an Integrated Insufflation System, and Conventional Insufflation#903851ClinicalTrials.gov
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib#827428ClinicalTrials.gov
• Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors#904379ClinicalTrials.gov
• A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors#980957ClinicalTrials.gov
• Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors#828027ClinicalTrials.gov
• INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme#840374ClinicalTrials.gov
• Safety, Tolerability, and Pharmacokinetics of EVT801 in Patients With Advanced Solid Tumours#865404ClinicalTrials.gov
• Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.#1053925NCBI PubMed Central
• A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies#812777ClinicalTrials.gov
• A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer#321716ClinicalTrials.gov
• Could molecular variations be predictive in right and left colon cancer in different gender and age groups?#358730PLOS
• Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium#370791HAL (France)
• An Observational Chart Review Study To Describe The Real-World Outcomes And Use Of Avelumab In Combination With Axitinib For Treatment Of Patients With aRCC In The UK#864743ClinicalTrials.gov
• Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)#238110ClinicalTrials.gov
• Racial differences in kidney cancer histology and outcome: a nationwide study from the UroCCR Cohort#261957HAL (France)
• GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors#905121ClinicalTrials.gov
• Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab, Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs-SBRT)#146457ClinicalTrials.gov
• Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States#475599Figshare
• Impact of the PRISM-care Multidisciplinary Oncology Program on Secured Drug Intake of Patients With Kidney Cancer#800172ClinicalTrials.gov
• A Prospective, Single-Arm, Multicenter Clinical Study of High-Risk Localized and Locally Advanced Renal Clear Cell Carcinoma#917603ClinicalTrials.gov
• A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.#373613ClinicalTrials.gov
• Analysis of factors affecting the upstaging and downstaging of renal cell carcinoma from T1 to T3a and the impact of different surgical approaches on patient prognosis and survival: a multicenter retrospective study.#280954NCBI PubMed Central
• Vaccination With Dendritic Cells Pulsed With Autologous Tumor Homogenate in Combination With HD-IL2 and Immunomodulating Radiotherapy in Metastatic RCC#435769ClinicalTrials.gov
• A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors#882426ClinicalTrials.gov